Received FDA Agreement Under Special Protocol Assessment (SPA) for the CoMpass Phase 3 Clinical TrialPositive Clinical Efficacy Updates of Bel-sar for Early-Stage Choroidal Melanoma from the Ongoing Phase 2 Clinical Trial with Suprachoroidal Administration Presented at AAO 2023Preliminary Data from Phase 1 Trial in.
Received FDA Agreement Under Special Protocol Assessment for the CoMpass Phase 3 Clinical Trial
Positive Clinical Efficacy Updates of Bel-sar for Early-Stage Choroidal Melanoma from the Ongoing.
J. Jill Hopkins, M.D., Appointed as Chief Medical Officer and President of Research & DevelopmentMark Plavsic, Ph.D., Appointed as Chief Technology OfficerBOSTON (BUSINESS WIRE) Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC).